[go: up one dir, main page]

WO2003045901A3 - Guanidine derivatives - Google Patents

Guanidine derivatives Download PDF

Info

Publication number
WO2003045901A3
WO2003045901A3 PCT/GB2003/000339 GB0300339W WO03045901A3 WO 2003045901 A3 WO2003045901 A3 WO 2003045901A3 GB 0300339 W GB0300339 W GB 0300339W WO 03045901 A3 WO03045901 A3 WO 03045901A3
Authority
WO
WIPO (PCT)
Prior art keywords
group
fused
cycloaliphatic
guanidine derivatives
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2003/000339
Other languages
French (fr)
Other versions
WO2003045901A2 (en
Inventor
Hazel Joan Dyke
George Martin Buckley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech R&D Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Priority to AU2003202091A priority Critical patent/AU2003202091A1/en
Publication of WO2003045901A2 publication Critical patent/WO2003045901A2/en
Publication of WO2003045901A3 publication Critical patent/WO2003045901A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Guanidine derivatives of formula (I) are described: wherein: R' is an aliphatic, cycloaliphatic or cycloalkyl-alkyl- group; R2 is an optionally substituted aromatic, heteroaromatic group, aryl-fused cycloaliphatic, heteroaryl-fused cycloaliphatic, aryl-fused heterocycloaliphatic or heteroaryl-fused heterocycloaliphatic group; R3 is a -CN, -COR5, -OR6, -CON(R7)R8, S02R5 or S02N(R7)R8 group; R4 is an optionally substituted heteroaromatic group; and the salts, solvates, hydrates, tautomers, isomers, N-oxides thereof. The compounds are potent inhibitors of IMPDH and are of use as immunosuppressants, anti-cancer agents, anti-inflammatory agents, antipsoriatic and anti-viral agents.
PCT/GB2003/000339 2002-04-10 2003-01-28 Guanidine derivatives Ceased WO2003045901A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003202091A AU2003202091A1 (en) 2002-04-10 2003-01-28 Guanidine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0208224.6 2002-04-10
GBGB0208224.6A GB0208224D0 (en) 2002-04-10 2002-04-10 Chemical compounds

Publications (2)

Publication Number Publication Date
WO2003045901A2 WO2003045901A2 (en) 2003-06-05
WO2003045901A3 true WO2003045901A3 (en) 2003-07-31

Family

ID=9934563

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/000339 Ceased WO2003045901A2 (en) 2002-04-10 2003-01-28 Guanidine derivatives

Country Status (3)

Country Link
AU (1) AU2003202091A1 (en)
GB (1) GB0208224D0 (en)
WO (1) WO2003045901A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2511521C (en) 2002-12-30 2012-02-07 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20090275099A1 (en) * 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
AU2006244068B9 (en) 2005-05-10 2012-10-25 Incyte Holdings Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
CA2634198C (en) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2007095050A2 (en) * 2006-02-09 2007-08-23 Incyte Corporation N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
JP5319532B2 (en) 2006-09-19 2013-10-16 インサイト・コーポレイション N-hydroxyamidino heterocycle as a modulator of indoleamine 2,3-dioxygenase
CL2007002650A1 (en) 2006-09-19 2008-02-08 Incyte Corp COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS.
SG192485A1 (en) 2008-07-08 2013-08-30 Incyte Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
US9169199B2 (en) 2010-12-08 2015-10-27 Lycera Corporation Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
WO2012078869A1 (en) 2010-12-08 2012-06-14 Lycera Corporation Pyridonyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
ES2639439T3 (en) 2010-12-08 2017-10-26 Lycera Corporation Inhibitors of F1F0-ATPases of pyrazolylguanidine type and their therapeutic uses
US9580391B2 (en) 2012-06-08 2017-02-28 Lycera Corporation Saturated acyl guanidine for inhibition of F1F0-ATPase
WO2013185045A1 (en) 2012-06-08 2013-12-12 Lycera Corporation Indazole guanidine f1f0-atpase inhibitors and therapeutic uses thereof
EP2866893A4 (en) 2012-06-08 2015-12-23 Lycera Corp Heterocyclic guanidine f1f0-atpase inhibitors
SG11201603433UA (en) 2013-11-08 2016-05-30 Incyte Corp Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
EP3080089B1 (en) 2013-12-10 2019-05-08 Lycera Corporation Trifluoromethyl pyrazolyl guanidine f1fo-atpase inhibitors and therapeutic uses thereof
CA2931792A1 (en) 2013-12-10 2015-06-18 Lycera Corporation N-substituted pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
AU2014363958B2 (en) 2013-12-10 2018-11-08 Lycera Corporation Alkylpyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
CN109970675A (en) * 2018-05-28 2019-07-05 中国医学科学院医药生物技术研究所 A group of thiourea compounds and their preparation method and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045108A1 (en) * 1996-05-30 1997-12-04 Children's Hospital Medical Center Guanidino derivatives as inhibitors of the cytotoxic effect of peroxynitrite
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
WO2001004102A1 (en) * 1999-07-07 2001-01-18 Astrazeneca Uk Limited Quinazoline derivatives
US6420403B1 (en) * 1998-10-29 2002-07-16 Edwin J. Iwanowicz Inhibitors of IMPDH enzyme

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
WO1997045108A1 (en) * 1996-05-30 1997-12-04 Children's Hospital Medical Center Guanidino derivatives as inhibitors of the cytotoxic effect of peroxynitrite
US6420403B1 (en) * 1998-10-29 2002-07-16 Edwin J. Iwanowicz Inhibitors of IMPDH enzyme
WO2001004102A1 (en) * 1999-07-07 2001-01-18 Astrazeneca Uk Limited Quinazoline derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

Also Published As

Publication number Publication date
AU2003202091A8 (en) 2003-06-10
AU2003202091A1 (en) 2003-06-10
WO2003045901A2 (en) 2003-06-05
GB0208224D0 (en) 2002-05-22

Similar Documents

Publication Publication Date Title
WO2003045901A3 (en) Guanidine derivatives
DK0889877T3 (en) Meta-substituted phenylene derivatives and their use as alpha-beta3 integrin antagonists or inhibitors
DE60204452D1 (en) [1,5] pyridine derivatives
HU9500240D0 (en) New prolin-amide derivatives and pharmaceutical compositions containing them as active component
NO986055D0 (en) New heterocyclic compounds, their preparation, pharmaceutical preparations
NO20025821L (en) 2-aminocarbonyl-9H-purine
YU49312B (en) CRYSTAL HYDRATE DERIVATIVES OF 3,4,4-TRISUPSTITUTED - PEPERIDINYL-N-ALKYL CARBOXYLATES, THEIR INTERMEDIATES AND THE PROCEDURE FOR THE PREPARATION
ATE301653T1 (en) PYRAZOLOPYRIDINES
FI962155A0 (en) New 9-hydroxypyrido (1,2-a) pyrimidin-4-one ether derivatives
LV12496A (en) Novel guanidine mimics as factor xa inhibitors
DK2314582T3 (en) Heterocyclic compounds as antiviral agents
ES2179318T3 (en) DERIVATIVES OF CINAMIC ACID AND ITS USE AS INTEGRINE ANTAGONISTS.
AU2002213421A1 (en) Condensed pyridoindole derivatives
MY129796A (en) Novel anti-inflammatory androstane derivatives
NO20035583D0 (en) Imidazo` 1,2-A pyridine derivatives for prophylaxis and treatment of herpes viral infections
WO2001094345A3 (en) Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
ATE300541T1 (en) PYRAZOLOPYRIDINE DERIVATIVES
ATE223419T1 (en) CONDENSED THIADIAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
IL163625A0 (en) Alkoxy-pyridine derivatives and pharmaceutical compositions containing the same
NZ516100A (en) Streptogramin derivatives, preparation and compositions containing them
AU2002213419A1 (en) Condensed pyridoindole derivatives
NO983444D0 (en) Benzo (c) quinolizine derivatives, their preparation and use as 5 <alfa> reductase inhibitors
AU2001261707A1 (en) Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives
NO20022123L (en) Oxoxazole derivatives for use as inhibitors of phosphodiesterase VII
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP